Accessibility Menu
Viveve Medical Stock Quote

Viveve Medical (OTC: VIVE)

$0.00
(50.0%)
+0.00
Price as of February 6, 2026, 2:19 p.m. ET

KEY DATA POINTS

Current Price
$0.00
Daily Change
(50.0%) +$0.00
Day's Range
$0.00 - $0.00
Previous Close
$0.00
Open
$0.00
Beta
-78.73
Volume
233
Average Volume
10,421
Market Cap
$3.2K
Market Cap / Employee
$0.00M
52wk Range
$0.00 - $0.02
Revenue
N/A
Gross Margin
N/A
Dividend Yield
N/A
EPS
N/A
CAPs Rating
N/A
Industry
Healthcare Equipment and Supplies

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Viveve Medical Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
VIVE+50%-99.99%-84.88%-100%
S&P+13.95%+78.35%+12.25%+1,590%

Viveve Medical Company Info

Viveve Medical, Inc. engages in the design, development, manufacture, and marketing of platform medical technology. It offers cryogen-cooled monopolar radio frequency technology, which delivered through a radiofrequency generator, hand piece and treatment tip. The Viveve system is a non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. The company was founded on March 3, 1987 and is headquartered Englewood, CO.

News & Analysis

No results found

No news articles found for Viveve Medical.

Financial Health

General

No data available

No data available for this period.

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

No data available

No data available for this period.

Liabilities

No data available

No data available for this period.

Ratios

No data available

No data available for this period.

Cash Flow

No data available

No data available for this period.

Valuation

MetricYoY Change

No results found

No podcast episodes available.

No results found

No transcripts available.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.